FGP
NRIX icon

Freestone Grove Partners’s Nurix Therapeutics NRIX Stock Holding History

Freestone Grove Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,724
Closed -$315K – 724
2024
Q4 		$315K Buy
+16,724
New +$383K ﹤0.01% 461

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freestone Grove Partners's NRIX Position: Q1 2025 in Review

Freestone Grove Partners sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 16,724 shares — an estimated $315K sold.

Freestone Grove Partners first reported a position in NRIX in Q4 2024 and held it in 1 quarter. The position peaked at $315K in Q4 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Freestone Grove Partners reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 16,724 Nurix Therapeutics shares in Q1 2025, an estimated $315K.
  • Freestone Grove Partners first reported a position in Nurix Therapeutics in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Nurix Therapeutics position peaked at $315K in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.